Trial Profile
An open label phase IIa trial evaluating the safety and efficacy of EPO906 in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2011
Price :
$35
*
At a glance
- Drugs Patupilone (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 25 Jul 2005 New trial record.